GPP
FOLD

Great Point Partners’s Amicus Therapeutics FOLD Stock Holding History

Great Point Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,400
Closed -$125K – 40
2017
Q2 		$125K Buy
+12,400
New +$99.8K 0.02% 38

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Great Point Partners's FOLD Position: Q3 2024 in Review

Great Point Partners sold out of Amicus Therapeutics (FOLD) in Q3 2024, closing a stake of 1,495,500 shares — an estimated $14.8M sold.

Great Point Partners first reported a position in FOLD in Q2 2021 and held it in 8 quarters. The position peaked at $18.2M in Q4 2023. 293 funds tracked by Wall St. Rank hold FOLD as of Q3 2024.

  • Great Point Partners reported no remaining Amicus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Great Point Partners sold 1,495,500 Amicus Therapeutics shares in Q3 2024, an estimated $14.8M.
  • Great Point Partners first reported a position in Amicus Therapeutics in Q2 2021 and held it in 8 quarters.
  • Great Point Partners's Amicus Therapeutics position peaked at $18.2M in Q4 2023.
  • 293 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2024.

Based on Great Point Partners's 13F filing for Q3 2024, filed 13 Nov 2024.